Skip to main content
SpringerLink
Log in

Discovery of Tumor Markers

  • Chapter
  • First Online:
Advances in Cancer Treatment

  • 742 Accesses

Abstract

This chapter discusses about the diagnosis of cancer, emphasizing the importance of early diagnosis in cancer as well as the importance of tumor markers that help in the diagnosis of cancer. This chapter also focuses on the main tumor markers used in the clinic and their importance in diagnosing the type of cancer in which they are used. Some of the markers are CEA, PSA, PAP, HER-2, BTA, telomerase, K-ras, CA 15.3, CA 19.9, CA 72.4, CA 125, NMP 22, p53, AFP, and β-hCG. This chapter also discusses about cancer staging, the criteria adopted by the TNM system to obtain a correct staging, and its importance as a parameter in defining cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Academies of Sciences, Engineering, and Medicine (2015) Improving diagnosis in health care. National Academies Press, Washington, DC

    Google Scholar 

  2. National Research Council (2003) Fulfiling the potential of cancer prevention and early detection. National Academies Press, Washington, DC

    Google Scholar 

  3. Church DJ, Krumme J, Kotwal S (2017) Evaluating soft-tissue lumps and bumps. Mo Med 114(4):289–294

    PubMed  PubMed Central  Google Scholar 

  4. Zhang BN, Cao XC, Chen JY, Chen J, Fu L, Hu X et al (2012) Guidelines on the diagnosis and treatment of breast cancer (2011 edition). Gland Surg 1(1):39–61

    PubMed  PubMed Central  Google Scholar 

  5. Connolly JL, Schnitt SJ, Wang HH, Longtine JA, Dvorak A, Dvorak HF (2003) Role of the surgical pathologist in the diagnosis and management of the cancer patient. In: Holland-Frei cancer medicine, 6th edn. BC Decker, Hamilton

    Google Scholar 

  6. Gilligan TD, Hayes DF, Seidenfeld J, Temin S (2010) ASCO clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J Oncol Pract 6(4):199–202

    Article  PubMed  PubMed Central  Google Scholar 

  7. Vaidyanathan K, Vasudevan DM (2012) Organ specific tumor markers: what’s new? Indian J Clin Biochem 27(2):110–120

    Article  CAS  PubMed  Google Scholar 

  8. Capelozzi VL (2001) Entendendo o papel de marcadores biológicos no câncer de pulmão. J de Pneumologia 27(6):321–328

    Google Scholar 

  9. Nagpal M, Singh S, Singh P, Chauhan P, Zaidi MA (2016) Tumor markers: a diagnostic tool. Natl J Max Surg 7(1):17–20

    Article  Google Scholar 

  10. Sharma S (2009) Tumor markers in clinical practice: general principles and guidelines. Indian J Med Paediatr Oncol 30:1–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hirata BKB, Oda JMM, Guembarovski RL, Ariza CB, Oliveira CEC, Watanabe MAE (2014) Molecular markers for breast cancer: prediction on tumor behavior. Dis Mark 2014:513158

    Google Scholar 

  12. Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F (2016) Clinically meaningful use of blood tumor markers in oncology. BioMed Res Int 2016:9795269

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Roy S, Dasgupta A, Kar K (2013) Comparison of urinary and serum CA 19–9 as markers of early stage urothelial carcinoma. Int Braz J Urol 39(5):631

    Article  PubMed  Google Scholar 

  14. Wagner IC, Guimarães MJB, Silva LKN, Melo FM, Muniz MTC (2007) Evaluation of serum and pleural levels of the tumor markers CEA, CYFRA21-1 and CA 15–3 in patients with pleural effusion. J Brasileiro de Pneumologia 33(2):185

    Article  Google Scholar 

  15. Aghagolzadeh P, Radpour R (2016) New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol 22(25):5678–5693

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kamel HFM, Al-Amodi HSB (2016) Cancer biomarkers. Intechopen. London, United Kingdom

    Google Scholar 

  17. Raman G, Wallace B, Patel K, Lau J, Trikalinos TA (2011) Update on horizon scans of genetic tests currently available for clinical use in cancers. Agency for Healthcare Research and Quality. Rockville, Maryland

    Google Scholar 

  18. Gabant P, Forrester L, Nichols J, Reeth TV, Mees CD, Pajack B et al (2002) Alpha-fetoprotein, the major fetal serum protein, is not essential for embryonic development but is required for female fertility. Proc Natl Acad Sci U S A 99(20):12865–12870

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bialecki ES, Di Bisceglie AM (2005) Diagnosis of hepatocellular carcinoma. HPB (Oxford) 7(1):26–34

    Article  Google Scholar 

  20. Lopez JB (2005) Recent developments in the first detection of hepatocellular carcinoma. Clin Biochemist Rev 26(3):65–79

    Google Scholar 

  21. Adigun OO, Khetarpal S (2020) Alpha fetoprotein (AFP, maternal serum fetoprotein, MSAFP). StatPearls Publishing, USA

    Google Scholar 

  22. El-Bahrawy M (2011) α-fetoprotein-producing non-germ cell tumors of the urological system. Rev Urol 13(1):14–19

    PubMed  PubMed Central  Google Scholar 

  23. Milose JC, Filson CP, Weizer AZ, Hafez KS, Montgomery JS (2012) Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. Open Access J Urol 4:1–8

    CAS  Google Scholar 

  24. Syu SH, Chang CL, Shih HJ (2019) Testicular mixed germ cell tumor presenting with seizure as the initial symptom: a case report and literature review. Int Braz J Urol 45(3):629

    Article  PubMed  PubMed Central  Google Scholar 

  25. Betz D, Fane K (2020) Human chorionic gonadotropin (HCG). StatPearls Publishing, USA

    Google Scholar 

  26. Elnour A (2018) Elevated human chorionic gonadotropin HCG serum level in germ cell testicular tumor. MOJ Proteomics Bioinform 7(1):43–44

    Article  Google Scholar 

  27. Boyd CA, Riall TS (2012) Unexpected gynecological findings during abdominal surgery. Curr Probl Surg 49(4):195–251

    Article  PubMed  PubMed Central  Google Scholar 

  28. Campos G, Feldhaus IMF, Santos LG, Souza LWCO (2017) Aplicação laboratorial do β-HCG como marcador tumoral para diagnóstico do câncer. Caderno Saúde e Desenvolvimento 11(6):5–14

    Google Scholar 

  29. Holzel WGE, Beer R, Deschner W, Griesmacher A, Muller MM (1995) Individual reference ranges of CA 15–3, MCA and CEA in recurrence of breast cancer. Scand J Clin Lab Invest 55(sup221):93

    Article  Google Scholar 

  30. Lauro S, Trasatti L, Bordin F, Lanzetta G, Bria E, Gelibter A et al (1999) Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 19(4C):3511–3515

    CAS  PubMed  Google Scholar 

  31. Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L et al (2006) Intensive post-operative follow up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 6:269

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Steger GG, Mader R, Derfler K, Moser K, Dittrich C (1989) Mucin-like cancer-associated antigen (MCA compared with CA15-3 in advanced breast cancer). Klin Wochenschr 67(16):813–817

    Article  CAS  PubMed  Google Scholar 

  33. Veljkovic M, Veljkovic S (2010) The risk of breast cervical, endometrial and ovarian cancer in oral contraceptive users. Medicinski Pregled 63(9–10):657–661

    Article  PubMed  Google Scholar 

  34. Fu Y, Li H (2016) Assessing clinical significance of serum CA15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: a meta-analysis. Med Sci Monit 22:3154–3162

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Mudduwa LKB, Wijayaratne GB, Peiris HH, Gunasekera SN, Abeysiriwardhana D, Liyanage N (2018) Elevated pre-surgical CA 15–3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis. Int J Women’s Health 10:329–335

    Article  CAS  Google Scholar 

  36. Almeida JRC, Pedrosa NL, Leite JB, Fleming TRP, Carvalho VH, Cardoso AAA (2007) Marcadores tumorais: revisão de literatura. Revista Brasileira de Cancerologia 53(3):305–316

    Article  Google Scholar 

  37. Mattar R, Andrade CRA, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA (2002) Preoperative serum levels of CA 72–4, CEA, CA 19–9, and alpha-fetoprotein in patients with gastric cancer. Revista do Hospital das Clínicas 57(3):89

    Article  PubMed  Google Scholar 

  38. Stieber P, Molina R, Chan DW, Fritsche HÁ, Beyrau R, Bonfrer JMG et al (2003) Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clin Lab 49(1–2):15–24

    CAS  PubMed  Google Scholar 

  39. Vizcarra E, Lluch A, Cibrián R, Jarque F, Alberola V, Belloch V et al (1996) Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 37(3):209–216

    Article  CAS  PubMed  Google Scholar 

  40. Al-azawi D, Kelly G, Myers E, McDermott EW, Hill ADK, Duffy MJ et al (2006) CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 6:220

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Chu WG, Ryu DW (2016) Clinical significance of serum CA 15-3 as a prognostic parameter during follow-up periods in patients with breast cancer. Ann Surg Treat Res 90(2):57–63

    Article  CAS  PubMed  Google Scholar 

  42. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L et al (2014) Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 134(11):2513–2522

    Article  CAS  PubMed  Google Scholar 

  43. Morais MB (2016) Signs and symptoms associated with digestive tract development. J de Pediatria 92(3):S46

    Article  Google Scholar 

  44. Basu A, Seth S, Chauhan AK, Bansal N, Arora K, Mahaur A (2016) Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy. Ann Trans Med 4(4):71

    Google Scholar 

  45. Chandana G, Vishwanathan B, Malik MA, Reddy SK, Raghavendra DS (2017) Role of serum CEA as tumor marker for predicting presence of pelvic and paraaortic lymph node metastasis in SCC of uterine cervix. J Cancer Prev Curr Res 8(2):00274

    Google Scholar 

  46. Saito G, Sadahiro S, Kamata H, Miyakita H, Okada K, Tanaka A et al (2017) Monitoring of serum carcinoembryonic antigen levels after curative resection of colon cancer: cutoff values determined according to preoperative levels enhance the diagnostic accuracy for recurrence. Oncology 92(5):276–282

    Article  CAS  PubMed  Google Scholar 

  47. Sørensen CG, Karlsson WK, Pommergaard HC, Burcharth J, Rosenberg J (2016) The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence – a systematic review. Int J Surg 25:134–144

    Article  PubMed  Google Scholar 

  48. Budman LI, Kassouf W, Steinberg JR (2008) Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2(3):212–221

    Article  PubMed  PubMed Central  Google Scholar 

  49. Darwiche F, Parekh DJ, Gonzalgo ML (2015) Biomarkers for non-muscle invasive bladder cancer: current tests and future promise. Indian J Urol 31(4):273–282

    Article  PubMed  PubMed Central  Google Scholar 

  50. Ranganathan P, Aggarwal R (2018) Common pitfalls in statistical analysis: understanding the properties of diagnostic tests – part 1. Perspect Clin Res 9(1):40–43

    Article  PubMed  PubMed Central  Google Scholar 

  51. Lamarca A, Barriuso J (2012) Urine telomerase for diagnosis and surveillance of bladder cancer. Adv Urol 2012:693631

    Article  PubMed  PubMed Central  Google Scholar 

  52. Morii A, Komiya A, Okumura A, Fuse H (2010) Telomerase activity in bladder cancer tissue. Exp Ther Med 1(1):85–88

    Article  PubMed  PubMed Central  Google Scholar 

  53. Sanchini MA, Bravaccini S, Medri L, Gunelli R, Nanni O, Monti F et al (2004) Urine telomerase: an important marker in the diagnosis of bladder cancer. Neoplasia 6(3):234–239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI (2008) Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10(2):120–135

    PubMed  PubMed Central  Google Scholar 

  55. Viola-Magni M, Cataldi S, Marocco D (2017) Bladder cancer markers and recent innovations. Intechopen. London, United Kingdom

    Google Scholar 

  56. Goodison S, Rosser CJ, Urquidi V (2013) Bladder cancer detection and monitoring: assessment of urine-and blood-based marker tests. Mol Diagn Ther 17(2):71–84

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Szymanska B, Sawicka E, Guzik A, Zdrojowy R, Dlugosz A (2017) The diagnostic value of nuclear matrix proteins in bladder cancer in the aspect of environmental risk from carcinogens. BioMed Res Int 2017:9643139

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Lai RS, Hsu HK, Lu JY, Ger LP, Lai NS (1996) CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Chest 109(4):995–1000

    Article  CAS  PubMed  Google Scholar 

  59. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J et al (2000) Tumor markers (CEA, CA 125, CYFRA 21.1, SCC and NSE) in non small cell lung cancer (NSCLC) patients as an aid in histological diagnosis and prognosis: comparison with the main clinical and pathological prognostic factors. Tumor Biol 24(4):209–218

    Article  CAS  Google Scholar 

  60. Takada M, Masuda N, Matsuura E, Kusunoki Y, Matui K, Nakagawa K et al (1995) Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer 71(1):160–165

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ilié M (2018) Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. Cancers 10(4):108

    Article  PubMed Central  CAS  Google Scholar 

  62. Madu CO, Lu Y (2010) Novel diagnostic biomarkers for prostate cancer. J Cancer 1:150–177

    Article  PubMed  PubMed Central  Google Scholar 

  63. Taira A, Merrick G, Wallner K, Dattoli M (2007) Reviving the acid phosphatase test for prostate cancer. Prostate 21(8):1003

    Google Scholar 

  64. Ilic D, Neuberger MM, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane Database Syst Rev (1):CD004720

    Google Scholar 

  65. Pentyala S, Whyard T, Pentyala S, Muller J, Pfail J, Parmar S et al (2016) Prostate cancer markers: an update. Biomed Rep 4(3):263–268

    Article  PubMed  PubMed Central  Google Scholar 

  66. Nogueira L, Corradi R, Eastham JA (2009) Prostatic specific antigen for prostate cancer detection. Int Braz J Urol 35(5):521–531

    Google Scholar 

  67. Descotes JL (2019) Diagnosis of prostate cancer. Asian J Urol 6(2):129–136

    Article  PubMed  PubMed Central  Google Scholar 

  68. Leite KR, Srougi M, Dall’Oglio MF, Sanudo A, Camara-Lopes LH (2008) Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL. Int Braz J Urol 34(3):283

    Article  PubMed  Google Scholar 

  69. Leslie SW, Soon-Sutton TL, Sajjad H, Siref LE (2020) Prostate cancer. StatPearls Publishing, USA

    Google Scholar 

  70. Bottoni P, Scatena R (2015) The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol 867:229

    Article  CAS  PubMed  Google Scholar 

  71. Welander CE (1992) What do CA 125 and other antigens tell us about ovarian cancer biology? Acta Obstet Gynecol Scand Suppl 155:85–93

    Article  CAS  PubMed  Google Scholar 

  72. Crombach G, Scharl A, Wurz H (1989) CA 125 in normal tissues and carcinomas of the uterine cervix, endometrium and fallopian tube. II. immunoradiometric determination in secretions, tissue extracts and serum. Arch Gynecol Obstet 244(2):113–122

    Article  CAS  PubMed  Google Scholar 

  73. Scholler N, Urban N (2007) CA 125 in ovarian cancer. Biomark Med 1(4):513–523

    Article  CAS  PubMed  Google Scholar 

  74. Bast RC (2010) Commentary: CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 116(12):2850–2853

    Article  PubMed  Google Scholar 

  75. Gupta D, Lis CG (2009) Role of CA125 in predicting ovarian cancer survival – a review of the epidemiological literature. J Ovarian Res 2:13

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Rastogi M, Gupta S, Sachan M (2016) Biomarkers towards ovarian cancer diagnostics: present and future prospects. Braz Arch Biol Technol 59:e16160070

    Google Scholar 

  77. Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 3(2):105–119

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Ballehaninna UK, Chamberlain RS (2011) Serum CA 19-9 as a biomarker for pancreatic cancer – a comprehensive review. Indian J Surg Oncol 2(2):88–100

    Article  PubMed  PubMed Central  Google Scholar 

  79. Wu Z, Kuntz AI, Wadleigh RG (2013) CA 19–9 tumor marker: is it reliable? case report in a patient with pancreatic cancer. Clin Adv Hematol Oncol 11(1):50

    PubMed  Google Scholar 

  80. Hoskovec D, Varga J, Konecná E, Antos F (2012) Levels of CEA and Ca 19–9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers. Acta Cirurgia Brasileira 27(6):410

    Article  Google Scholar 

  81. Kaur M, Dalal V, Bhatnagar A, Siraj F (2016) Pancreatic tuberculosis with markedly elevated CA 19-9 levels: a diagnostic pitfall. Oman Med J 31(6):446–449

    Article  PubMed  PubMed Central  Google Scholar 

  82. Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS (2019) Usefulness of carbohydrate antigen 19-9 test in healthy people and necessity of medical follow-up in individuals with elevated carbohydrate antigen 19-9 level. Korean J Family Med 40(5):314–322

    Article  Google Scholar 

  83. Malaguarnera G, Giordano M, Paladina I, Rando A, Uccello M, Basile F et al (2011) Markers of bile duct tumors. World J Gastrointest Oncol 3(4):49–59

    Article  PubMed  PubMed Central  Google Scholar 

  84. Henson DE, Albores-Saavedra J (2001) Pathology of incipient neoplasia. Oxford University Press, Oxford

    Google Scholar 

  85. Novak EM, Rego EM (2012) Physiopathogenesis of hematological cancer. Bentham Science Publishers, United Arab Emirates

    Book  Google Scholar 

  86. Chen J (2016) The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harbor Perspect Med 6(3):a026104

    Article  CAS  Google Scholar 

  87. Ozaki T, Nakagawara A (2011) Role of p53 in cell death and human cancers. Cancers 3(1):994–1013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Klumb CENP, Resende LMM, Tajara EH, Bertelli ECP, Rumjanek VM, Maia RC (2001) p53 gene analysis in childhood B non-Hodgkin’s lymphoma. Sao Paulo Med J 119(6):212

    Article  CAS  PubMed  Google Scholar 

  89. Oliver M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor Perspect Biol 2(1):a001008

    Google Scholar 

  90. Silberman H, Silberman AW (2012) Principles and practice of surgical oncology: a multidisciplinary approach to difficult problems. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  91. Ackroyd SA, Goetsch L, Brown J, Houck K, Wang C, Hernandez E (2019) Pancreaticobiliary metastasis presenting as primary mucinous ovarian neoplasm: a systematic literature review. Gynecol Oncol Rep 28:109–115

    Article  PubMed  PubMed Central  Google Scholar 

  92. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C (2002) CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 22(4):2311–2316

    CAS  PubMed  Google Scholar 

  93. Lenhard MS, Nehring S, Nagel D, Mayr D, Kirschenhofer A, Hertlein L et al (2009) Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. Clin Chem Lab Med 47(5):537–542

    Article  CAS  PubMed  Google Scholar 

  94. Jancik S, Drábek J, Radzioch D, Hajdúch M (2010) Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010:150960

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Li S, Balmain A, Counter CM (2018) A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev 18:767–777

    Article  CAS  Google Scholar 

  96. Murtaza BN, Bibi A, Rashid MU, Khan YI, Chaudri MS, Shakoori AR (2013) Spectrum of K ras mutations in Pakistani colorectal cancer patients. Braz J Med Biol Res 47(1):35

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S et al (2018) KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer 17:33

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Yang H, Liang SQ, Schmid RA, Peng RW (2019) New horizons in KRAS-mutant lung cancer: dawn after darkness. Front Oncol 9:953

    Article  PubMed  PubMed Central  Google Scholar 

  99. Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A et al (2015) Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol 10(3):431–437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Ferreira PMP, Pessoa C (2017) Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: new evidences and old challenges. Braz J Pharmaceut Sci 53(2):e16076

    Google Scholar 

  101. Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:852748

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  102. Wieduwilt MJ, Moasser MM (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65(10):1566–1584

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Bagci O, Kurtgoz S (2015) Amplification of cellular oncogenes in solid tumors. N Am J Med Sci 7(8):341–346

    Article  PubMed  PubMed Central  Google Scholar 

  104. English DP, Roque DM, Santin AD (2013) HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther 17(2):85–99

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Gutierrez C, Schiff R (2011) HER 2: biology, detection, and clinical implications. Arch Pathol Lab Med 135(1):55–62

    Article  PubMed  PubMed Central  Google Scholar 

  106. Martin TA, Ye L, Sanders AJ, Lane J, Jiang WG (2013) Cancer invasion and metastasis: molecular and cellular perspective. In: Madame Curie bioscience database [Internet]. Landes Bioscience

    Google Scholar 

  107. Gress DM, Edge SB, Greene FL, Washington MK, Asare EA, Brierley JD et al (2017) Principles of cancer staging. In: AJCC cancer staging manual, 8th edn. Springer-Verlag, New York, pp 3–30

    Chapter  Google Scholar 

  108. Rosen RD, Sapra A (2020) TNM classification. StatPearls Publishing, USA

    Google Scholar 

  109. Bruening W, Sullivan N, Paulson EC, Zafar H, Mitchell M, Treadwell J et al (2014) Imaging tests for the staging of colorectal cancer. Comparative Effectiveness Reviews142:14-EHC046-EF

    Google Scholar 

  110. Miziara JM, Rocha ET, Miziara JEA, Garcia GF, Simões MIP, Lopes MA et al (2011) Preoperative nodal staging of non-small cell lung cancer using 99mTc-sestamibi spect/ct imaging. Clinics 66(11):1901

    Article  PubMed  PubMed Central  Google Scholar 

  111. Smeltzer SC, Bare BG (1992) Brunner & Suddarth’s textbook of medical-surgical nursing. JB Lippincott, Philadelphia

    Google Scholar 

  112. Koukis I, Gkiozos I, Ntanos I, Kainis E, Syrigos KN (2013) Clinical and surgical-pathological staging in early non-small cell lung cancer. Oncol Rev 7(1):e7

    Article  PubMed  PubMed Central  Google Scholar 

  113. Mclaughlin S, Shephard J, Wallen E, Maygarden S, Carson CC, Pruthi RS (2007) Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. Int Braz J Urol 33(1):25

    Article  PubMed  Google Scholar 

  114. Boeker M, França F, Bronsert P, Schulz S (2016) TNM-O: ontology support for staging of malignant tumours. J Biomed Seman 7:64

    Article  Google Scholar 

  115. Brierley J, O’Sullivan B, Asamura H, Byrd D, Huang SH, Lee A et al (2019) Global consultation on cancer staging: promoting consistent understanding and use. Nat Rev Clin Oncol 16:763–771

    Article  PubMed  PubMed Central  Google Scholar 

  116. Roland N, Porter G, Fish B, Makura Z (2016) Tumour assessment and staging: United Kingdom national multidisciplinary guidelines. J Laryngol Otol 130(Suppl 2):S53–S58

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil

    Iago Dillion Lima Cavalcanti & José Cleberson Santos Soares

Authors
  1. Iago Dillion Lima Cavalcanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Cleberson Santos Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cavalcanti, I.D.L., Soares, J.C.S. (2021). Discovery of Tumor Markers. In: Advances in Cancer Treatment. Springer, Cham. https://doi.org/10.1007/978-3-030-68334-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-68334-4_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-68333-7

  • Online ISBN: 978-3-030-68334-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation